Log in to search using one of your social media accounts:

 

Sacubitril/valsartan cost  effective for HF in Netherlands
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2017 Category: Drugs & Pharmacology Source Type: news

Valturna (Aliskiren and Valsartan, USP Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 13, 2017 Category: Drugs & Pharmacology Source Type: news

The Time is Now to Move Far Beyond the Pill
There has been a lot of talk about ‘beyond the pill'strategies for many years, as companies create services and solutions that are complementary to their drugs. More recently, with the many changes affecting healthcare, pharma companies are adjusting their business models and looking at strategies to improve patient outcomes and diversify revenue sources that go far beyond the pill.Wellness programs and chronic disease management are common approaches, offering opportunities for companies to increase customer engagement leading to improved outcomes. For example, Biogen has used Fitbits to monitor the walking activity...
Source: EyeForPharma - April 10, 2017 Category: Pharmaceuticals Authors: Dr Andree Bates Source Type: news

Sacubitril/valsartan cost effective for heart failure
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2017 Category: Drugs & Pharmacology Source Type: news

Mar 31 Cardiology News Mar 31 Cardiology News
High-sensitivity troponin testing, dabigatran during AF ablation, valve-in-valve TAVR, Impella, and the ARNI valsartan/sacubitril's effect on HbA1c are discussed in this week's podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 31, 2017 Category: Cardiology Tags: Cardiology News Source Type: news

HbA1c Fell in Diabetics on Sacubitril/Valsartan: PARADIGM-HF HbA1c Fell in Diabetics on Sacubitril/Valsartan: PARADIGM-HF
That extra benefit for diabetics in the trial may be yet another reason to consider switching patients with reduced-EF heart failure from ACE inhibitors or ARBs to the newer agent, say observers.Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 30, 2017 Category: Cardiology Tags: Cardiology News Source Type: news

New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entresto® (sacubitril/valsartan) tablets improved glycemic control, as assessed by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril[1]. (Source: World Pharma News)
Source: World Pharma News - March 20, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Ezra Announces FDA Acceptance Of Filing Of New Drug Application For EZR-104 For The Treatment Of Hypertension And Heart Failure
LITTLE ROCK, Ark., Jan. 18, 2017 -- (Healthcare Sales & Marketing Network) -- Ezra Innovations, LLC (Ezra) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for an investigational drug product, EZ... Biopharmaceuticals, Cardiology, FDA Ezra Innovations, valsartan, Rubireten (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 19, 2017 Category: Pharmaceuticals Source Type: news

Entresto (Sacubitril and Valsartan Film-coated Tablets for Oral Administration) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 28, 2016 Category: Drugs & Pharmacology Source Type: news

Deals this week: Laboratorios Farmaceuticos ROVI, Proteros biostructures, Bionor Pharma
Laboratorios Farmaceuticos ROVI and Novartis Farmaceutica have entered a co-marketing agreement to market and distribute Neparvis (Sacubitril/ Valsartan) in Spain. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 25, 2016 Category: Pharmaceuticals Source Type: news

PARADIGM-HF: MRA and Sacubitril/Valsartan Cut Hyperkalemia Risk PARADIGM-HF: MRA and Sacubitril/Valsartan Cut Hyperkalemia Risk
For those wishing to use a mineralocorticoid-receptor antagonist in HF with a RAAS inhibitor,"it is safer to do so by combining an MRA with sacubitril/valsartan than with an ACE inhibitor."Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 22, 2016 Category: Cardiology Tags: Cardiology News Source Type: news

In Heart Failure Patients, Severe Hyperkalemia Less Common with Sacubitril/Valsartan Than Enalapril (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Among patients with heart failure who are taking a mineralocorticoid receptor antagonist (MRA), the risk for severe hyperkalemia is lower … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 14, 2016 Category: Primary Care Source Type: news

Exforge HCT (Amlodipine Valsartan Hydrochlorothiazide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2016 Category: Drugs & Pharmacology Source Type: news

Entresto (sacubitril and valsartan)
Title: Entresto (sacubitril and valsartan)Category: MedicationsCreated: 7/17/2015 12:00:00 AMLast Editorial Review: 9/21/2016 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - September 21, 2016 Category: Cardiology Source Type: news

Hypotension No Reason to Avoid Sacubitril/Valsartan: PARADIGM-HF Hypotension No Reason to Avoid Sacubitril/Valsartan: PARADIGM-HF
Although cited as one barrier to embracing the drug for HF, hypotension per se in the sacubitril/valsartan run-in didn't keep it from besting ACE inhibitors after randomization, researchers say.Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 20, 2016 Category: Cardiology Tags: Cardiology News Source Type: news

Diovan (Valsartan) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 1, 2016 Category: Drugs & Pharmacology Source Type: news

Sacubitril/valsartan good value for heart failure with reduced LVEF
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 31, 2016 Category: Drugs & Pharmacology Source Type: news

Sacubitril-Valsartan Seems Cost-Effective for Heart Failure with Reduced Ejection Fraction (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD The combination treatment sacubitril-valsartan (Entresto) appears to be a cost-effective therapy for patients with heart failure and … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 29, 2016 Category: Primary Care Source Type: news

Sacubitril-valsartan cost-effective for treating reduced ejection fraction heart failure
(American College of Physicians) Sacubitril-valsartan is reasonably cost effective compared to widely-used therapies for reducing mortality and morbidity in patients with reduced ejection fraction heart failure. The findings are published in Annals of Internal Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 29, 2016 Category: Cancer & Oncology Source Type: news

ARNI Cuts 30-Day Readmission in Heart Failure: PARADIGM-HFARNI Cuts 30-Day Readmission in Heart Failure: PARADIGM-HF
"The post-hospitalization period following clinical stabilization may be the ideal time to initiate the therapy" in low-EF patients who can tolerate the drug, sacubitril/valsartan, say observers. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

ARNI Cuts 30-Day Readmission in Heart Failure: PARADIGM-HF ARNI Cuts 30-Day Readmission in Heart Failure: PARADIGM-HF
& quot;The post-hospitalization period following clinical stabilization may be the ideal time to initiate the therapy & quot; in low-EF patients who can tolerate the drug, sacubitril/valsartan, say observers. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 20, 2016 Category: Cardiology Tags: Cardiology News Source Type: news

Sacubitril plus valsartan reduces early readmission risk in HF
The risk of readmission within 30 days of heart failure hospitalisation is reduced by a quarter for patients receiving sacubitril/valsartan compared with those receiving enalapril, an analysis of PARADIGM-HF trial data shows. (Source: MedWire News)
Source: MedWire News - July 13, 2016 Category: Consumer Health News Tags: Heart failure Source Type: news

Sacubitril/Valsartan Cuts Readmissions After Heart Failure Hospitalization (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Patients taking the heart failure treatment sacubitril/valsartan are less likely than those taking enalapril to be readmitted after an HF hospitalization, according to … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 11, 2016 Category: Primary Care Source Type: news

Sacubitril/Valsartan Cost-effective in Low-EF HF: AnalysisSacubitril/Valsartan Cost-effective in Low-EF HF: Analysis
"Not only do patients who take sacubitril/valsartan live longer, they actually have a better quality of life because they get hospitalized less," said a researcher. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

Sacubitril/valsartan in heart failure: Differing added benefit
Due to a subgroup effect, reviewers have found that there is an indication of a minor added benefit for patients with diabetes, and an indication of a considerable added benefit for patients without diabetes, when using Sacubitril/valsartan in heart failure. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 20, 2016 Category: Science Source Type: news

Sacubitril/valsartan in heart failure: Differing added benefit
(Institute for Quality and Efficiency in Health Care) Due to a subgroup effect, there is an indication of a minor added benefit for patients with diabetes, and an indication of a considerable added benefit for patients without diabetes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 20, 2016 Category: Global & Universal Source Type: news

Byvalson (Nebivolol and Valsartan Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 15, 2016 Category: Drugs & Pharmacology Source Type: news

Allergan Announces FDA Approval of Byvalson (nebivolol and valsartan) for Hypertension
DUBLIN, June 6, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the approval of Byvalson (nebivolol and valsartan) 5 mg/ 80 mg tablets, by the U.S. Food and Drug Administration (FDA) for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 7, 2016 Category: Drugs & Pharmacology Source Type: news

Allergan Announces FDA Approval of BYVALSON(TM) (nebivolol and valsartan)
First and Only Fixed-Dose Combination of a Beta Blocker and Angiotensin II Receptor Blocker for Treatment of Hypertension DUBLIN, June 6, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), a leading global pharmaceutical company, tod... Biopharmaceuticals, Cardiology, FDAAllergan, BYVALSON, nebivolol, valsartan, hypertension (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 6, 2016 Category: Pharmaceuticals Source Type: news

Updated Heart Failure Guidelines Include Two New Treatments (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Valsartan/sacubitril and ivabradine are recommended for heart failure in updated guidelines from the American Heart Association, the American College of Cardiology, and the Heart Failure Society of America.Valsartan/sacubitril is an angiotensin receptor-neprilysin inhibitor (ARNI). By blocking that receptor, it inhibits … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 22, 2016 Category: Primary Care Source Type: news

Entresto Gets Boost in Updated HF Guidelines
(MedPage Today) -- Valsartan/sacubitril earns Class I recommendation (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 21, 2016 Category: Cardiology Source Type: news

Thousands of patients to benefit from £3-a-day treatment rolled out in hospitals from next month 
Sacubitril valsartan cuts death rates by a fifth when compared with enalapril – the current ‘gold standard’ heart failure treatment – and will be rolled out to hospitals in the next month. (Source: the Mail online | Health)
Source: the Mail online | Health - April 27, 2016 Category: Consumer Health News Source Type: news

8 Things Every Woman Should Know About Her Libido
By Hallie Levine Here today, gone tomorrow--your libido can be puzzling, to say the least. But that ebb and flow is completely natural, says Lauren Streicher, MD, clinical associate professor of obstetrics and gynecology at Northwestern Memorial Hospital in Chicago: "All women go through periods when they feel especially frisky, as well as times when they just seem to have lost their mojo." Read on to learn about the many reasons your libido may come and go, and how to find it when you miss it. Curious about aphrodisiacs? We've got those too, from strawberries to Savasana. RELATED: 9 Things Every Woman Must Know ...
Source: Healthy Living - The Huffington Post - March 28, 2016 Category: Consumer Health News Source Type: news

SMC accepts breakthrough treatment Entresto™ for use in patients with symptomatic chronic heart failure
Sacubitril/valsartan represents a breakthrough therapeutic option for adult patients with symptomatic chronic heart failure with reduced ejection fraction (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 9, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Healthcare professionals Practical therapeutics Cardiovascular medicine Patient care chronic heart failure Latest News sacubitril/valsartan scottish medicines consortium Source Type: news

Entresto (Sacubitril and Valsartan Film-coated Tablets for Oral Administration) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 24, 2016 Category: Drugs & Pharmacology Source Type: news

Valsartan and Hydrochlorothiazide Tablet, Film Coated (New - Discontinuation)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 17, 2016 Category: Drugs & Pharmacology Source Type: news

Valsartan Tablets (New - Discontinuation)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 17, 2016 Category: Drugs & Pharmacology Source Type: news

Breakthrough drug for heart failure now available in the UK
Novartis drug Entresto™ (sacubitril/valsartan) approved for use in adults with symptomatic chronic heart failure with reduced ejection fraction reduces mortality risk compared with current treatment according to study (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 20, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Cardiovascular medicine Legislation & regulation Patient care British Society for Heart Failure chronic heart failure ejection fraction Entresto HFrEF Latest News mortality risk PARADIGM Source Type: news

Drug hailed as breakthrough for heart patients to be available on the NHS
Cardiologists say sacubitril valsartan, which costs £3 a day, is the biggest step forward in their field in 15 years and will be made available to more than half a million heart patients in Britain on the NHS by May. (Source: the Mail online | Health)
Source: the Mail online | Health - January 20, 2016 Category: Consumer Health News Source Type: news

Recently approved heart drug poses potential risk to brain & eye, Temple researcher warns
(Temple University Health System) Patients with mild heart failure stand to benefit from a new drug that can halt the progression of their disease and reduce their risk of cardiovascular-related death. But the drug -- a tablet that combines the agents valsartan and sacubitril, sold under the trade name Entresto by drugmaker Novartis -- may be too good to be true, according to Arthur M. Feldman, M.D., Ph.D., Executive Dean of the Lewis Katz School of Medicine at Temple University. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 9, 2015 Category: Global & Universal Source Type: news

LCZ696 for HF Keeps Edge Over ACE-I Across Range of LVEF, Dosage LCZ696 for HF Keeps Edge Over ACE-I Across Range of LVEF, Dosage
PARADIGM-HF analyses tackle issues likely to be seen in clinical practice, now that valsartan-sacubitril is available for heart failure; but efficacy across dosages doesn't mean ignoring evidence-based targets. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 29, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

EMA Committee Backs Approval of Sacubitril/Valsartan (Entresto)EMA Committee Backs Approval of Sacubitril/Valsartan (Entresto)
The recommendation is for heart-failure patients with reduced ejection fraction. However, the organization notes it shouldn't be started in those with low blood pressure or high potassium levels. International Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 25, 2015 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Novartis's new heart failure drug Entresto gets Swissmedic approval
Novartis has received approval from Swissmedic for Entresto (sacubitril/valsartan), which reduces the risk of cardiovascular mortality and morbidity in patients with heart failure with reduced ejection fraction (HFrEF). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 20, 2015 Category: Pharmaceuticals Source Type: news

Is The Superiority Of Entresto Just An Illusion?
Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as a mega-blockbuster. Some suggest $10 billion per annum peak sales may be achievable, making it one of the biggest selling drugs of all time. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 14, 2015 Category: Pharmaceuticals Authors: David Grainger Source Type: news

FDA Approves First-in-Class Combo Drug for Heart Failure
A pill combining valsartan and sacubitril has received first-in-class approval for heart failure under the Food and Drug Administration's priority review program. Entresto offers practitioners a new option for reducing risk of cardiovascular death and hospitalization in patients with NYHA class II-IV heart failure and reduced ejection fraction. (Source: Caring for the Ages)
Source: Caring for the Ages - August 29, 2015 Category: Health Management Authors: Judith M. Orvos Source Type: news

Aug 21 Cardiology NewsAug 21 Cardiology News
Early use of NOACs or warfarin, ICD generator change, obesity, social determinants of health, ABIM, and valsartan/sacubitril are the topics discussed by Dr John Mandrola. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 21, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

CardioBreak: CMS $$ Up for Several CV Tx, Diovan Ditched
(MedPage Today) -- Recent developments of interest in cardiovascular medicine (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 10, 2015 Category: Cardiology Source Type: news

Aug 7 Cardiology News Aug 7 Cardiology News
Early use of NOACs or warfarin, ICD generator change, obesity, social determinants of health, ABIM, and valsartan/sacubitril are the topics discussed by Dr John Mandrola. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 7, 2015 Category: Cardiology Tags: Cardiology News Source Type: news